Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVONE6)

Drug Name
Epidermal growth factor Drug Info
Synonyms
62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF
Indication
Disease Entry ICD 11 Status REF
Vulnerary ND56.Z Approved [1]
Wound healing EL8Y Phase 2 [2]
Cross-matching ID
PubChem CID
56841751
CAS Number
CAS 62229-50-9
TTD Drug ID
DMVONE6
INTEDE Drug ID
DR1921

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Metabolized By Carboxypeptidase M (CPM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bradykinin DM4R6UV N. A. N. A. Phase 1 [6]
Drug(s) Targeting Epidermal growth factor (EGF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hebervis DMZ4A0R Oral mucositis DA01.11 Investigative [7]
Drug(s) Targeting Epidermal growth factor receptor (EGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Hepatocellular carcinoma 2C12.02 Approved [8]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [9]
Gefitinib DM15F0X Solid tumour/cancer 2A00-2F9Z Approved [10]
Erlotinib DMCMBHA Non-small-cell lung cancer 2C25.Y Approved [11]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [12]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [4]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [13]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [14]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [15]
Nitroglycerin DMQ2491 Angina pectoris BA40 Approved [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor (EGF) TTED8JB EGF_HUMAN Modulator [3]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Modulator [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Carboxypeptidase M (CPM) Main DME DE1TNRG CBPM_HUMAN Substrate [5]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4916).
3 Repurposing of the epidermal growth factor. Journal of Commercial Biotechnology (2011) 17, 45-52.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
5 Extracellular conversion of epidermal growth factor (EGF) to des-Arg53-EGF by carboxypeptidase M. J Biol Chem. 1995 Jul 21;270(29):17154-8.
6 Interactions between carboxypeptidase M and kinin B1 receptor in endothelial cells. Inflamm Res. 2019 Oct;68(10):845-855.
7 Leadership in BioBusiness. Dr Gurinder S Shahi. Page(36).
8 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
9 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
10 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
11 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
12 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
13 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
14 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
15 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
16 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.